Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Dates: 2004 - 2006
Funding: Medical Research Council
Collaborators: Institute of Cancer, Royal Marsden Hospital
Information: Helen Campbell

The aim of the United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Adjuvant Breast Cancer (ABC) Trial was to evaluate whether adding chemotherapy and/or ovarian suppression to tamoxifen is effective and cost-effective in the treatment of women with early breast cancer.

All women recruited to the trial received tamoxifen. For pre/peri-menopausal women, there were three randomisation options:

  • chemotherapy versus no chemotherapy;
  • ovarian suppression versus no ovarian suppression;
  • chemotherapy versus no chemotherapy and ovarian suppression versus no ovarian suppression.

Post-menopausal women were randomised to chemotherapy or no chemotherapy.

The trial's primary outcome measures were overall and relapse free survival and were examined for two principal comparisons: ± ovarian suppression in pre/peri-menopausal women, and ± chemotherapy for all women. The economic evaluation also carried out for these comparisons uses patient-specific and published resource use data relating to adjuvant therapies, treatments for any therapy induced toxicities and recurrences, and numbers of visits made to GPs, outpatient clinics and other health care professionals. Patient outcome is measured as both survival and quality adjusted survival (or QALYs), calculated by weighting survival by health state utilities derived by administering the EuroQol EQ-5D questionnaire to a sub-group of patients in the trial.

The economic evaluation conducted alongside this trial has now been completed.


Campbell, HE, Taylor, MA, Harris, AL, and Gray, AM (2009). An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer, 101(7):1074-84.